+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

India GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Application (Diabetes, Obesity), By Route of Administration (Parenteral, Oral), By Product, By Distribution Channel, And Segment Forecasts, 2025 - 2030

  • PDF Icon

    Report

  • 150 Pages
  • June 2025
  • Region: India
  • Grand View Research
  • ID: 6111305
Description Jump to:

India GLP-1 Receptor Agonist Market Trends

The India GLP-1 receptor agonist market size was estimated at USD 110.55 million in 2024 and is projected to grow at a CAGR of 34.3% from 2025 to 2030. The market is driven by the rising incidence of chronic conditions such as type 2 diabetes and obesity, increasing R&D activities for novel therapeutics, patent expiry, and the entry of generic alternatives. According to the International Diabetes Federation report of 2024, 8.98 million adults are prone to diabetes, and approximately 185 million people will succumb to diabetes by 2050 in India.

India has witnessed a significant rise in metabolic disorders due to rapid urbanization, sedentary lifestyles, and poor dietary habits. With rising obesity rates, the demand for effective treatments is continuously increasing. GLP-1 receptor agonists are recognized as a promising therapeutic class for managing both obesity and type 2 diabetes by improving insulin sensitivity and promoting weight loss. These drugs have gained popularity due to their proven efficacy, making them a sought-after treatment for millions suffering from these chronic conditions in India.

The Ministry of Ayush, India, has implemented various initiatives to combat obesity and promote weight management through Ayurveda. The All India Institute of Ayurveda (AIIA) in New Delhi offers specialized treatments such as Panchakarma, Ayurvedic medicines, dietary guidelines, and practicing yoga. The Central Council for Research in Ayurvedic Sciences (CCRAS) is primarily involved in formulating, developing, and promoting Ayurvedic medicines. CCRAS conducts clinical trials to evaluate the safety and efficacy of Ayurvedic formulations and practices in managing lifestyle-related disorders such as diabetes, hypertension, obesity, and stress-related ailments.

The Ayurswasthya Yojana supports community-based healthcare initiatives to address obesity and related lifestyle disorders. Through strategic collaboration with the Council of Scientific and Industrial Research (CSIR), the program integrates traditional Ayurvedic knowledge with modern scientific approaches, thereby advancing research and improving the prevention and management of these conditions.

India GLP-1 Receptor Agonist Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the India GLP-1 receptor agonist market report based on product, application, route of administration, and distribution channel:

Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Ozempic (semaglutide)
  • Trulicity
  • Mounjaro (tirzepatide)
  • Wegovy (semaglutide)
  • Rybelsus (oral semaglutide)
  • Saxenda
  • Victoza (liraglutide)
  • Zepbound
  • Other Products (SOLIQUA (lixisenatide), Bydureon)

Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Type 2 Diabetes Mellitus
  • Obesity

Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Parenteral
  • Oral

Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

This product will be delivered within 2 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Application
1.2.3. Route of Administration
1.2.4. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. India GLP-1 Receptor Agonist Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. India GLP-1 Receptor Agonist Market: Product Business Analysis
4.1. Product Market Share, 2024 & 2030
4.2. Product Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Product, 2018 to 2030 (USD Million)
4.4. Ozempic (semaglutide)
4.4.1. Ozempic (semaglutide) Market, 2018 - 2030 (USD Million)
4.5. Trulicity
4.5.1. Trulicity Market, 2018 - 2030 (USD Million)
4.6. Mounjaro (tirzepatide)
4.6.1. Mounjaro (tirzepatide) Market, 2018 - 2030 (USD Million)
4.7. Wegovy (semaglutide)
4.7.1. Wegovy (semaglutide)Market, 2018 - 2030 (USD Million)
4.8. Rybelsus (oral semaglutide)
4.8.1. Rybelsus (oral semaglutide) Market, 2018 - 2030 (USD Million)
4.9. Saxenda
4.9.1. Saxenda Market, 2018 - 2030 (USD Million)
4.10. Victoza (liraglutide)
4.10.1. Victoza (liraglutide) Market, 2018 - 2030 (USD Million)
4.11. Zepbound
4.11.1. Zepbound Market, 2018 - 2030 (USD Million)
4.12. Others
4.12.1. Others Market, 2018 - 2030 (USD Million)
Chapter 5. India GLP-1 Receptor Agonist Market: Application Business Analysis
5.1. Application Market Share, 2024 & 2030
5.2. Application Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Application, 2018 to 2030 (USD Million)
5.4. Type 2 Diabetes Mellitus
5.4.1. Type 2 Diabetes Mellitus Market, 2018 - 2030 (USD Million)
5.5. Obesity
5.5.1. Obesity Market, 2018 - 2030 (USD Million)
Chapter 6. India GLP-1 Receptor Agonist Market: Route of Administration Business Analysis
6.1. Route of Administration Market Share, 2024 & 2030
6.2. Route of Administration Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
6.4. Parenteral
6.4.1. Parenteral Market, 2018 - 2030 (USD Million)
6.5. Oral
6.5.1. Oral Market, 2018 - 2030 (USD Million)
Chapter 7. India GLP-1 Receptor Agonist Market: Distribution Channel Business Analysis
7.1. Distribution Channel Market Share, 2024 & 2030
7.2. Distribution Channel Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
7.4. Hospital Pharmacies
7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
7.5. Retail Pharmacies
7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
7.6. Online Pharmacies
7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)
Chapter 8. India GLP-1 Receptor Agonist Market: Country Estimates & Trend Analysis
8.1. Country Market Share Analysis, 2024 & 2030
8.2. Country Market Dashboard
8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
8.4. India
8.4.1. India
8.4.1.1. Key Country Dynamics
8.4.1.2. Target Disease Prevalence
8.4.1.3. Regulatory Framework
8.4.1.4. Reimbursement Framework
8.4.1.5. India GLP-1 Receptor Agonist Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Participant Overview
9.2. Company Market Position Analysis
9.3. Company Categorization
9.4. Strategy Mapping
9.5. Company Profiles/Listing
9.5.1. AstraZeneca
9.5.1.1. Overview
9.5.1.2. Financial Performance
9.5.1.3. Product Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Novo Nordisk A/S
9.5.2.1. Overview
9.5.2.2. Financial Performance
9.5.2.3. Product Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Eli Lilly and Co
9.5.3.1. Overview
9.5.3.2. Financial Performance
9.5.3.3. Product Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Biocon
9.5.4.1. Overview
9.5.4.2. Financial Performance
9.5.4.3. Product Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. Sanofi
9.5.5.1. Overview
9.5.5.2. Financial Performance
9.5.5.3. Product Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. Glenmark Pharmaceuticals Ltd.
9.5.6.1. Overview
9.5.6.2. Financial Performance
9.5.6.3. Product Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Cipla
9.5.7.1. Overview
9.5.7.2. Financial Performance
9.5.7.3. Product Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. Sun Pharmaceuticals Industries Ltd
9.5.8.1. Overview
9.5.8.2. Financial Performance
9.5.8.3. Product Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. Zydus Group
9.5.9.1. Overview
9.5.9.2. Financial Performance
9.5.9.3. Product Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Lupin
9.5.10.1. Overview
9.5.10.2. Financial Performance
9.5.10.3. Product Benchmarking
9.5.10.4. Strategic Initiatives
9.5.11. Dr. Reddy’s Laboratories Ltd
9.5.11.1. Overview
9.5.11.2. Financial Performance
9.5.11.3. Product Benchmarking
9.5.11.4. Strategic Initiatives
9.5.12. Alkem
9.5.12.1. Overview
9.5.12.2. Financial Performance
9.5.12.3. Product Benchmarking
9.5.12.4. Strategic Initiatives
9.5.13. Piramal Pharma Limited
9.5.13.1. Overview
9.5.13.2. Financial Performance
9.5.13.3. Product Benchmarking
9.5.13.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 India GPL-1 receptor agonist market, by region, 2018 - 2030 (USD Million)
Table 4 India GPL-1 receptor agonist market, by product, 2018 - 2030 (USD Million)
Table 5 India GPL-1 receptor agonist market, by application, 2018 - 2030 (USD Million)
Table 6 India GPL-1 receptor agonist market, by route of administration, 2018 - 2030 (USD Million)
Table 7 India GLP-1 receptor agonist market, by distribution channel, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 India GLP-1 Receptor Agonist market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and application outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 India GLP-1 Receptor Agonist market dynamics
Fig. 12 India GLP-1 Receptor Agonist market: Porter’s five forces analysis
Fig. 13 India GLP-1 Receptor Agonist market: PESTLE analysis
Fig. 14 Product market, 2018 - 2030 (USD Million)
Fig. 15 Ozempic (semaglutide) market, 2018 - 2030 (USD Million)
Fig. 16 Trulicity market, 2018 - 2030 (USD Million)
Fig. 17 Mounjaro (tirzepatide) market, 2018 - 2030 (USD Million)
Fig. 18 Wegovy (semaglutide) market, 2018 - 2030 (USD Million)
Fig. 19 Rybelsus (oral semaglutide) market, 2018 - 2030 (USD Million)
Fig. 20 Saxenda market, 2018 - 2030 (USD Million)
Fig. 21 Victoza (liraglutide) market, 2018 - 2030 (USD Million)
Fig. 22 Zepbound market, 2018 - 2030 (USD Million)
Fig. 23 Other Products (SOLIQUA (lixisenatide), Bydureon) market, 2018 - 2030 (USD Million)
Fig. 24 Application market, 2018 - 2030 (USD Million)
Fig. 25 Type 2 Diabetes Mellitus market, 2018 - 2030 (USD Million)
Fig. 26 Obesity market, 2018 - 2030 (USD Million)
Fig. 27 Route of administration market, 2018 - 2030 (USD Million)
Fig. 28 Parenteral market, 2018 - 2030 (USD Million)
Fig. 29 Oral market, 2018 - 2030 (USD Million)
Fig. 30 Distribution Channel market, 2018 - 2030 (USD Million)
Fig. 31 Hospital Pharmacies market, 2018 - 2030 (USD Million)
Fig. 32 Retail Pharmacies market, 2018 - 2030 (USD Million)
Fig. 33 Online Pharmacies market, 2018 - 2030 (USD Million)
Fig. 34 India GLP-1 Receptor Agonist market revenue, by region
Fig. 35 Country marketplace: Key takeaways
Fig. 36 India country dynamics
Fig. 37 India GLP-1 receptor agonist market, 2018 - 2030 (USD Million)
Fig. 38 Company categorization
Fig. 39 Company market position analysis
Fig. 40 Strategic framework

Companies Mentioned

  • AstraZeneca
  • Novo Nordisk A/S
  • Eli Lilly and Co
  • Biocon
  • Sanofi
  • Glenmark Pharmaceuticals Ltd.
  • Cipla
  • Sun Pharmaceuticals Industries Ltd
  • Zydus Group
  • Lupin
  • Dr. Reddy’s Laboratories Ltd
  • Alkem
  • Piramal Pharma Limited

Related Topics

Related Reports

GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Product (Ozempic, Zepbound), By Application (Diabetes, Obesity), By Route Of Administration (Parenteral, Oral), By Region, And Segment Forecasts, 2025 - 2030 - Product Image

GLP-1 Receptor Agonist Market Size, Share & Trends Analysis Report By Product (Ozempic, Zepbound), By Application (Diabetes, Obesity), By Route Of Administration (Parenteral, Oral), By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 150 Pages
  • Global
From
GLP-1 Receptor Agonist Market by Drug Class, Drug Type, Route of Administration, Application, Distribution Channel - Global Forecast to 2030 - Product Image

GLP-1 Receptor Agonist Market by Drug Class, Drug Type, Route of Administration, Application, Distribution Channel - Global Forecast to 2030

  • Report
  • 184 Pages
  • Global
From
GLP-1 Receptor Agonist Market Report 2025 - Product Image

GLP-1 Receptor Agonist Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025 - Product Image

Glucagon-Like Peptide (GLP) Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • 180 Pages
  • Global
From
GLP-1 Receptor Agonist Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type - Product Image

GLP-1 Receptor Agonist Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type

  • Report
  • 73 Pages
  • Global
From

About the GLP-1 Receptor Agonist Market

The GLP-1 Receptor Agonist market is a subset of the Central Nervous System Drugs market. GLP-1 Receptor Agonists are drugs that act on the GLP-1 receptor, a protein found in the brain and other parts of the body. These drugs are used to treat a variety of conditions, including obesity, type 2 diabetes, and depression. GLP-1 Receptor Agonists work by stimulating the release of insulin and other hormones, which can help regulate blood sugar levels and reduce appetite. GLP-1 Receptor Agonists are typically administered as injections, and are often used in combination with other medications. They are generally well-tolerated, with few side effects. However, they can be expensive, and may not be covered by insurance. Some companies in the GLP-1 Receptor Agonist market include Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.